{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T14:58:40Z","timestamp":1789657120732,"version":"4.0.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Journal Armed Forces India"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.mjafi.2021.01.015","type":"journal-article","created":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T02:03:44Z","timestamp":1616551424000},"page":"296-301","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Association of CD 34 positive cell dose with engraftment kinetics in autologous peripheral blood stem cell transplant patients of multiple myeloma"],"prefix":"10.1016","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0998-9893","authenticated-orcid":false,"given":"Neerja","family":"Kushwaha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudeep","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohd Anas","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Philip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeevan","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6199-2205","authenticated-orcid":false,"given":"Amit Kumar","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6275-7269","authenticated-orcid":false,"given":"Rajneesh Kumar","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mjafi.2021.01.015_bib1","series-title":"Hoffbrand's Essential Haematology","author":"Hoffbrand","year":"2016"},{"key":"10.1016\/j.mjafi.2021.01.015_bib2","doi-asserted-by":"crossref","first-page":"101929","DOI":"10.1016\/j.ctrv.2019.101929","article-title":"Multiple myeloma: role of autologous transplantation","volume":"82","author":"Ntanasis-Stathopoulos","year":"2020","journal-title":"Canc Treat Rev"},{"issue":"16","key":"10.1016\/j.mjafi.2021.01.015_bib3","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S1470-2045(15)00389-7","article-title":"Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial","volume":"16","author":"Gay","year":"2015","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.mjafi.2021.01.015_bib4","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1182\/blood-2014-03-544759","article-title":"How we manage autologous stem cell transplantation for patients with multiple myeloma","volume":"124","author":"Gertz","year":"2014","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.mjafi.2021.01.015_bib5","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1182\/blood-2003-01-0073","article-title":"Controversy in hematology Transplantation for multiple myeloma\u202f: who , when , how often\u202f? High-dose therapy in multiple myeloma","volume":"102","author":"Blade","year":"2003","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.mjafi.2021.01.015_bib6","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41408-019-0205-9","article-title":"Current status of autologous stem cell transplantation for multiple myeloma","volume":"9","author":"Al Hamed","year":"2019","journal-title":"Blood Canc J"},{"issue":"11","key":"10.1016\/j.mjafi.2021.01.015_bib7","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.bbmt.2013.08.002","article-title":"Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma","volume":"19","author":"Costa","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.mjafi.2021.01.015_bib8","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.bbmt.2013.04.027","article-title":"Trends in use of and survival after autologous hematopoietic cell transplantation in north America, 1995-2005: significant improvement in survival for lymphoma and myeloma during a period of increasing recipient age","volume":"19","author":"McCarthy","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.mjafi.2021.01.015_bib9","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.clml.2018.12.010","article-title":"Hematopoietic progenitor cell mobilization for autologous stem cell transplantation in multiple myeloma in contemporary era","volume":"19","author":"Arora","year":"2019","journal-title":"Clin Lymphoma, Myeloma & Leukemia"},{"issue":"4","key":"10.1016\/j.mjafi.2021.01.015_bib10","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.transci.2018.05.031","article-title":"The relationship between CD34+ stem cell dose and time to neutrophil recovery in autologous haematopoietic stem cell recipients-A single centre experience","volume":"57","author":"Nath","year":"2018","journal-title":"Transfus Apher Sci"},{"issue":"4","key":"10.1016\/j.mjafi.2021.01.015_bib11","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.transci.2017.06.002","article-title":"The relationship of CD34+ dosage and platelet recovery following high dose chemotherapy and autologous CD34+ reinfusion in multiple myeloma","volume":"56","author":"Martin","year":"2017","journal-title":"Transfus Apher Sci"},{"issue":"1","key":"10.1016\/j.mjafi.2021.01.015_bib12","doi-asserted-by":"crossref","first-page":"34","DOI":"10.5001\/omj.2019.06","article-title":"Autologous peripheral blood stem cell transplantation among lymphoproliferative disease patients: factors influencing engraftment","volume":"34","author":"Hassan","year":"2019","journal-title":"Oman Med J"},{"issue":"5","key":"10.1016\/j.mjafi.2021.01.015_bib13","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/bjh.12946","article-title":"Bortezomib-Cyclophosphamide-Dexamethasone (VCD) versus Bortezomib-Thalidomide-Dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis","volume":"166","author":"Leiba","year":"2014","journal-title":"Br J Haematol"},{"issue":"21","key":"10.1016\/j.mjafi.2021.01.015_bib14","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood-2016-01-693580","article-title":"VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial","volume":"127","author":"Moreau","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.mjafi.2021.01.015_bib15","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1089\/scd.1.1996.5.213","article-title":"The ISHAGE guidelines for CD34+ cell determination by Flow cytometry","volume":"5","author":"Sutherland","year":"1996","journal-title":"J Hematother"},{"issue":"6","key":"10.1016\/j.mjafi.2021.01.015_bib16","doi-asserted-by":"crossref","first-page":"730","DOI":"10.4103\/ijmr.IJMR_1593_18","article-title":"High-dose chemotherapy followed by autologous stem cell transplant for multiple myeloma: predictors of long-term outcome","volume":"149","author":"Kumar","year":"2019","journal-title":"Indian J Med Res"},{"issue":"5","key":"10.1016\/j.mjafi.2021.01.015_bib17","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1159\/000478265","article-title":"Gender-specific aspects in patients with multiple myeloma undergoing autologous stem cell transplantation: a single-center experience","volume":"93","author":"Posch","year":"2017","journal-title":"Oncology"},{"issue":"February","key":"10.1016\/j.mjafi.2021.01.015_bib18","first-page":"1","article-title":"Body mass index does not impact hematopoietic progenitor cell mobilization for autologous hematopoietic cell transplantation","author":"Khouri","year":"2019","journal-title":"J Clin Apher"},{"issue":"11","key":"10.1016\/j.mjafi.2021.01.015_bib19","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.3324\/haematol.2016.150334","article-title":"Upfront autologous stem cell transplantation for newly diagnosed elderly multiple myeloma patients: a prospective multicenter study","volume":"101","author":"Garderet","year":"2016","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.mjafi.2021.01.015_bib20","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.bbmt.2010.11.021","article-title":"Transplanted CD34+ cell dose is associated with long-term platelet count recovery following autologous peripheral blood stem cell transplant in patients with non-hodgkin lymphoma or multiple myeloma","volume":"17","author":"Stiff","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.mjafi.2021.01.015_bib21","doi-asserted-by":"crossref","DOI":"10.1007\/s00277-020-04112-4","article-title":"Factors that predict delayed platelet recovery after autologous stem cell transplantation for lymphoma or myeloma","author":"Nagayama","year":"2020","journal-title":"Ann Hematol"},{"key":"10.1016\/j.mjafi.2021.01.015_bib22","article-title":"CD34+ Hematopoietic progenitor cell dose as a predictor of engraftment and survival in multiple myeloma patients undergoing autologous stem cell transplantation","author":"Alada\u011f Karakulak","year":"2020","journal-title":"Turkish J Med Sci"},{"issue":"4","key":"10.1016\/j.mjafi.2021.01.015_bib23","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/sj.bmt.1700671","article-title":"Relationship of CD34+ cell dose to early and late hematopoiesis following autologous peripheral blood stem cell transplantation","volume":"19","author":"Kiss","year":"1997","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.mjafi.2021.01.015_bib24","first-page":"13","article-title":"Daily measurements of blood CD34+ cells after stem cell mobilization predict stem cell yield and posttransplant hematopoietic recovery","volume":"6","author":"Remes","year":"1997","journal-title":"J Hematother Stem Cell Res"},{"issue":"3","key":"10.1016\/j.mjafi.2021.01.015_bib25","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1023\/A:1008252227512","article-title":"High-dose therapy with peripheral blood progenitor cell transplantation in multiple myeloma","volume":"8","author":"Goldschmidt","year":"1997","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.mjafi.2021.01.015_bib26","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1182\/blood.V85.2.588.588","article-title":"Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients","volume":"85","author":"Tricot","year":"1995","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.mjafi.2021.01.015_bib27","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.1182\/blood.V85.12.3754.bloodjournal85123754","article-title":"Sustained long-term hematopoiesis after myeloablative therapy with peripheral blood progenitor cell support","volume":"85","author":"Haas","year":"1995","journal-title":"Blood"}],"container-title":["Medical Journal Armed Forces India"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0377123721000241?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0377123721000241?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T11:50:38Z","timestamp":1759837838000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0377123721000241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S0377123721000241"],"URL":"https:\/\/doi.org\/10.1016\/j.mjafi.2021.01.015","relation":{},"ISSN":["0377-1237"],"issn-type":[{"value":"0377-1237","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of CD 34 positive cell dose with engraftment kinetics in autologous peripheral blood stem cell transplant patients of multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Medical Journal Armed Forces India","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mjafi.2021.01.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Director General, Armed Forces Medical Services. Published by Elsevier, a division of RELX India Pvt. Ltd.","name":"copyright","label":"Copyright"}]}}